Management in acute liver failure

J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S104-15. doi: 10.1016/j.jceh.2014.11.005. Epub 2014 Dec 3.

Abstract

Acute liver failure (ALF) is a rare, potentially fatal complication of severe hepatic illness resulting from various causes. In a clinical setting, severe hepatic injury is usually recognised by the appearance of jaundice, encephalopathy and coagulopathy. The central and most important clinical event in ALF is occurrence of hepatic encephalopathy (HE) and cerebral edema which is responsible for most of the fatalities in this serious clinical syndrome. The pathogenesis of encephalopathy and cerebral edema in ALF is unique and multifactorial. Ammonia plays a central role in the pathogenesis. The role of newer ammonia lowering agents is still evolving. Liver transplant is the only effective therapy that has been identified to be of promise in those with poor prognostic factors, whereas in the others, aggressive intensive medical management has been documented to salvage a substantial proportion of patients. A small fraction of patients undergo liver transplant and the remaining are usually treated with medical therapy. Therefore, identification of the complications and causes of death in such patients, and use of appropriate prognostic models to identify those who need liver transplant and those who can be managed with medical treatment is a vital component of therapeutic strategy. In this review, we discuss the various pathogenetic mechanisms and treatment options available.

Keywords: AASLD, American Association For the Study of Liver; ALF, Acute Liver Failure; ALFED, Acute Liver Failure Early Dynamic Model; BBB, Blood Brain Barrier; BCAA, Branched Chain Amino acid; CBF, Cerebral Blood Flow; CPP, Cerebral Perfusion Pressure; CVVHD, Continuous Veno-Venous Hemodialysis; FFP, Fresh Frozen Plasma; GM-CSF, Granulocyte Macrophage Colony Stimulating Factor; HE, Hepatic Encephalopathy; ICU, Intensive Care Unit; IEI, Icterus Encephalopathy Interval; IL-1β, Interleukin-1 beta; IL6, Interlekin 6; INR, International Normalized Ratio; LOLA, l-Ornithine L Aspartate; LOPA; LOPA, l-Ornithine Phenyl Acetate; MAP, Mean Arterial Pressure; NAC, N-Acetyl Cysteine; NO, Nitric Oxide; OLT, Orthotopic Liver Transplantation; PCWP, Pulmonary Capillary Wedge Pressure; PEEP, Positive End Expiratory Pressure; PT, Prothrombin Time; SIMV, Synchronous Intermittent mandatory Ventilation; SIRS, Systemic Inflammatory Response Syndrome; SPEAR, Selective Parenteral and Enteral Antibiotic Regimen; TNF-α, Tumor Necrosis Factor alfa; UCD, Urea Cycle Disorder; USALF, United States Acute liver Failure Study Group; ammonia; cerebral edema.

Publication types

  • Review